First Patient Dosed - Health Technology Insights

Lipocine Doses First Patient in Phase 3 LPCN 1154 Trial

June 26, 2025

Phase 3 Top Line Results Expected Q2 2026 Lipocine Inc, a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral

Bio-Thera Begins Phase 3 Trial for BAT8006 in Ovarian Cancer

June 25, 2025

Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that dosing has begun in a phase 3 clinical study

Categories

Tag: First Patient Dosed

Lipocine Doses First Patient in Phase 3 LPCN 1154 Trial

Bio-Thera Begins Phase 3 Trial for BAT8006 in Ovarian Cancer

Share With

Recent Posts

Nuclear Care Partners Backs Bipartisan Bill for Energy Workers’ Care

Lake Chelan Health Enters into Prime Vendor Agreement with Medline

Health Technology Insights: Latest News And Innovations – Roundup

INOVIO Announces Pricing of $25 Million Public Offering

Rhode Island Creates Rare Disease Advisory Council

Quick Links

Insights

Get in touch

Follow Us

Our Other Brands